Literature DB >> 15561871

Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae.

Dario Caronzolo1, Valeria Lucini, Marilou Pannacci, Silvia Grosso, Federica Colleoni, Franco Fraschini, Francesco Scaglione.   

Abstract

The in vitro and in vivo antichlamydial activities of dexamethasone and beclomethasone alone and in combination with an antibiotic were tested. In vitro, dexamethasone and beclomethasone decreased the number of inclusion-forming units versus the control number (P < 0.001). The combination of glucocorticoids with azithromycin, telithromycin, or levofloxacin was more active than antibiotics used alone (P < 0.001). The combination, tested in a murine Chlamydophila pneumoniae infection model, produced similar results.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15561871      PMCID： PMC529217          DOI： 10.1128/AAC.48.12.4878-4881.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma.

Authors:  P N Black; R Scicchitano; C R Jenkins; F Blasi; L Allegra; J Wlodarczyk; B C Cooper
Journal:  Eur Respir J       Date:  2000-02       Impact factor: 16.671

2.  Effects of antiasthma drugs on the growth of Chlamydophila pneumoniae in HEp-2 cells.

Authors:  Hayashi Komura; Hiroshi Matsushima; Kazunobu Ouchi; Mutsunori Shirai; Teruko Nakazawa; Susumu Furukawa
Journal:  J Infect Chemother       Date:  2003-06       Impact factor: 2.211

3.  Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.

Authors:  J Gieffers; H Füllgraf; J Jahn; M Klinger; K Dalhoff; H A Katus; W Solbach; M Maass
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

4.  Characterization of antiapoptotic activities of Chlamydia pneumoniae in human cells.

Authors:  S F Fischer; C Schwarz; J Vier; G Häcker
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Chlamydia pneumoniae activates IKK/I kappa B-mediated signaling, which is inhibited by 4-HNE and following primary exposure.

Authors:  Bernadette Donath; Claudia Fischer; Sharon Page; Sigrid Prebeck; Nikolaus Jilg; Marion Weber; Clarissa da Costa; Dieter Neumeier; Thomas Miethke; Korbinian Brand
Journal:  Atherosclerosis       Date:  2002-11       Impact factor: 5.162

6.  Aspirin inhibits Chlamydia pneumoniae-induced NF-kappa B activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth.

Authors:  Hiroshi Yoneda; Koshiro Miura; Hiroshi Matsushima; Kazuro Sugi; Tomoyuki Murakami; Kazunobu Ouchi; Katsuhiro Yamashita; Haruhide Itoh; Teruko Nakazawa; Michiyasu Suzuki; Mutsunori Shirai
Journal:  J Med Microbiol       Date:  2003-05       Impact factor: 2.472

Review 7.  Anti-inflammatory actions of glucocorticoids: molecular mechanisms.

Authors:  P J Barnes
Journal:  Clin Sci (Lond)       Date:  1998-06       Impact factor: 6.124

8.  Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp.

Authors:  R J Suchland; W M Geisler; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Distinct actions of prednisolone and dexamethasone towards osteocalcin and eosinophilic cationic protein in assumed clinically equivalent doses: a study in healthy men.

Authors:  E F L Dubois; M G M Derks; A H Zwinderman; P N R Dekhuijzen; C J Van Boxtel; D H Schweitzer
Journal:  Eur J Clin Pharmacol       Date:  2003-02-15       Impact factor: 2.953

10.  Chlamydia pneumoniae induces the expression of inhibitor of apoptosis 2 (c-IAP2) in a human monocytic cell line by an NF-kappaB-dependent pathway.

Authors:  Christian Wahl; Sonja Maier; Reinhard Marre; Andreas Essig
Journal:  Int J Med Microbiol       Date:  2003-11       Impact factor: 3.473
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.